MarketPulse

Ryoncil®

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Plans First R&D Day to Showcase Pipeline, New Cell Therapy Tech

Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.
MESORyoncil®cellular medicines
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Taps Regeneron Veteran as Clinical Chief to Expand Cell Therapy Pipeline

Mesoblast appoints veteran biotech executive Dr. Teresa Montagut as Head of Clinical Development, signaling acceleration in cell therapy pipeline expansion and Ryoncil® indication broadening.
MESOclinical developmentRyoncil®
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval